ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO419

Applicability of Mayo's Autosomal Dominant Polycystic Kidney Disease Prognostic Tool in the Southeast Asian ADPKD Population

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Cystic

Authors

  • Gan, Chye Chung, University of Malaya Faculty of Medicine, Kuala Lumpur, Wilayah Persekutuan, Malaysia
  • Goh, En Thong, University of Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia
  • Ooi, Shok Hoon, University of Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia
  • Leong, Wai Ling, University of Malaya Faculty of Medicine, Kuala Lumpur, Wilayah Persekutuan, Malaysia
  • Cheah, Peng Loon, University of Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia
  • Vijayananthan, Anushya, University of Malaya Faculty of Medicine, Kuala Lumpur, Wilayah Persekutuan, Malaysia
  • Lim, Soo Kun, University of Malaya Faculty of Medicine, Kuala Lumpur, Wilayah Persekutuan, Malaysia
Background

Mayo autosomal dominant polycystic kidney disease (ADPKD) prognostic tool revolved around the height-adjusted total kidney volume (HtTKV0) measurement using MRI at a single point of time adjusted with age0 and it was recognized as a strong predictor for kidney disease progression in patients with ADPKD. This study reports 24-month prospective longitudinal studies examining the applicability of the Mayo ADPKD prognostic tool in the Southeast Asian cohort in a tertiary center in Malaysia.

Methods

Convenience sampling was completed on March 2021. Patients were subjected to a single non-contrasted T2W-MRI kidney scan using the ellipsoid method with subsequent yearly blood samples collected for analysis. Total kidney volume0 (TKV0) was measured by 2 radiologists and the average of 2 results was recorded. Correlation of glomerular filtration rate generated from the Mayo ADPKD prognostic tool (eGFRMayo) and serum estimated glomerular filtration rate of patients according to 2009 CKD-EPIcreatinine (eGFR2009CKD-EPI) were tested with Spearman correlation coefficient and Bland-Altman analysis.

Results

A total of 50 patients were enrolled with a median age of 39.5 years (33.5, 58.0) and predominantly female (54%), and of Chinese (60%) ethnicity. Median TKV0 was 1233.8cm3 (697.2, 1995.8) and HtTKV0 was 727.9ml/m (447.0, 1180.9). Three patients dropped out at month 24. eGFRMayo correlated very strongly with eGFR2009CKD-EPI during the 24 months study with RS0=1.000 (bias of -0.196, precision=0.395), RS12=0.972 (bias of -0.204, precision=8.300), and RS24=0.952 (bias of 4.670, precision=10.930) respectively, p<0.001. eGFRMayo demonstrated an accuracy of 42.6 – 98% within 10mls/min/1.73m2 of serum eGFR2009CKD-EPI.

Conclusion

Mayo's ADPKD prognostic tool demonstrated its applicability to the Southeast Asian ADPKD population with a very strong correlation to eGFR2009CKD-EPI, low bias, and high precision. Long-term data with a larger sample size needs to be evaluated in future studies.

Spearman correlation coefficient & Bland-Altman analysis
VariablesSample size, nSpearman’s correlation coefficient (Rs)p-valueBias
(Mean difference)
Precision (±1.96SD of Mean Difference)Accuracy (P10) ,%
eGFR Mayo* vs eGFR 2009CKD-EPI at 0 month501.0000.000-0.1960.39598
eGFR Mayo* vs eGFR 2009CKD-EPI at 12 months500.9720.000-0.2048.30058
eGFR Mayo* vs eGFR 2009CKD-EPI at 24 months470.9520.0004.67010.93042.6

*Web app by Mayo Foundation & Medical Education & Research

Funding

  • Government Support – Non-U.S.